Free Trial

Elevation Oncology (ELEV) Insider Trading & Ownership

Elevation Oncology logo
$0.58 -0.05 (-7.30%)
(As of 12/20/2024 05:45 PM ET)

Elevation Oncology (NASDAQ:ELEV) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
8.10%
Number Of
Insiders Buying
(Last 3 Years)
0
Number Of
Insiders Selling
(Last 3 Years)
1
Amount Of
Insider Selling
(Last 3 Years)
$2.90 M
Get ELEV Insider Trade Alerts

Want to know when executives and insiders are buying or selling Elevation Oncology stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ELEV Insider Buying and Selling by Quarter

Elevation Oncology Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2022Global Strategic Fund I VenbioMajor ShareholderSell702,737$4.12$2,895,276.44  
(Data available from 1/1/2013 forward)

ELEV Insider Trading Activity - Frequently Asked Questions

The list of insiders at Elevation Oncology includes Global Strategic Fund I Venbio. Learn more on insiders at ELEV.

8.10% of Elevation Oncology stock is owned by insiders. Learn more on ELEV's insider holdings.

Elevation Oncology Key Executives

  • Mr. Joseph J. Ferra Jr. (Age 49)
    CEO, President & Director
    Compensation: $897.28k
  • Dr. David Dornan Ph.D. (Age 46)
    Chief Scientific Officer
    Compensation: $620.92k
  • Ms. Valerie Malyvanh Jansen M.D. (Age 46)
    Ph.D., Chief Medical Officer
    Compensation: $685.94k
  • Ms. Tammy Furlong CPA (Age 53)
    P.M.P., CFO & Secretary
  • Mr. Ryan Bloomer
    Head of Tech Ops
  • Candice Masse
    Senior Director of Corporate Communications & Investor Relations
  • Mr. Robert C. Yang
    Vice President of Legal Affairs
  • Mr. Biren Shah
    Senior Vice President of Business & Corporate Development


This page (NASDAQ:ELEV) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners